Acro Biomedical Overhauls Leadership, Installing New CEO and Chairman
ACBM filed a Executive and Board Changes on light trading volume (0.1× avg).
Summary
Acro Biomedical replaced its CEO, chairman, and CFO in a single day, installing Shao-Hsiang Shih as chairman and Jing-Zhou Chen as CEO/CFO amid severe cash constraints.
Key Events · Executive and Board Changes · ACBM
-
CEO and Chairman Resign
Yu-Ting Su resigned as director, chairman, and CEO effective upon appointment of a successor; no disagreement with the company was cited.
-
New Chairman Appointed
Shao-Hsiang Shih was appointed director and chairman effective September 2, 2026; he has served as Director of Administrative Management at Century Publishing Co. since 2020.
-
New CEO and CFO Appointed
Jing-Zhou Chen was appointed CEO and CFO effective September 2, 2026; he is founder and CEO of Dream Born Co., Ltd., a digital lifestyle and short-form video platform.
-
Financial Distress Context
The leadership change comes after the company reported only $3,648 in cash and a $444,789 working capital deficiency in its most recent 10-Q filed August 13, 2026.
Analysis · ACBM · Trade & Services
A complete change in top leadership took effect on September 2, 2026. Yu-Ting Su resigned as director, chairman, and CEO, and the board immediately appointed Shao-Hsiang Shih as chairman and Jing-Zhou Chen as CEO and CFO. The company is in severe financial distress — its last 10-Q showed only $3,648 in cash and a working capital deficiency of $444,789 — so a full executive overhaul at this moment is a material governance event. The new CEO brings experience in digital platforms and cloud kitchens, but no disclosed background in biomedical or healthcare, which raises questions about the company's strategic direction.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.5% of the 1882 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.18%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACBM was trading at $0.03 on OTC in the Trade & Services sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.00 to $9.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.